Paratek Pharmaceuticals Inc (NASDAQ:PRTK) – Equities research analysts at G.Research dropped their FY2024 earnings per share (EPS) estimates for Paratek Pharmaceuticals in a research note issued on Thursday, June 25th. G.Research analyst K. Kedra now anticipates that the specialty pharmaceutical company will post earnings of $0.90 per share for the year, down from their prior estimate of $0.95.
A number of other research analysts have also weighed in on PRTK. Wedbush reiterated an “outperform” rating on shares of Paratek Pharmaceuticals in a research note on Monday, March 9th. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research note on Tuesday, June 23rd. Finally, ValuEngine upgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. Eight equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus target price of $15.90.
Shares of PRTK stock opened at $5.11 on Monday. The company has a 50 day moving average of $4.58 and a 200-day moving average of $4.02. Paratek Pharmaceuticals has a 12-month low of $2.50 and a 12-month high of $5.89. The firm has a market cap of $208.75 million, a P/E ratio of -1.46 and a beta of 1.54.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its earnings results on Monday, May 11th. The specialty pharmaceutical company reported ($0.66) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.14. Paratek Pharmaceuticals had a negative net margin of 528.28% and a negative return on equity of 5,327.73%. The firm had revenue of $7.92 million for the quarter, compared to analysts’ expectations of $7.75 million.
Several hedge funds and other institutional investors have recently bought and sold shares of PRTK. Rock Springs Capital Management LP lifted its holdings in shares of Paratek Pharmaceuticals by 307.0% during the 1st quarter. Rock Springs Capital Management LP now owns 1,526,310 shares of the specialty pharmaceutical company’s stock worth $4,808,000 after acquiring an additional 1,151,310 shares during the last quarter. Balyasny Asset Management LLC bought a new stake in shares of Paratek Pharmaceuticals during the 1st quarter worth $1,071,000. Norges Bank bought a new stake in shares of Paratek Pharmaceuticals during the 4th quarter worth $1,165,000. Goldman Sachs Group Inc. lifted its holdings in shares of Paratek Pharmaceuticals by 157.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 341,322 shares of the specialty pharmaceutical company’s stock worth $1,376,000 after acquiring an additional 208,755 shares during the last quarter. Finally, General American Investors Co. Inc. lifted its holdings in shares of Paratek Pharmaceuticals by 24.7% during the 1st quarter. General American Investors Co. Inc. now owns 803,184 shares of the specialty pharmaceutical company’s stock worth $2,530,000 after acquiring an additional 158,861 shares during the last quarter. 43.41% of the stock is owned by institutional investors.
In other news, Chairman Michael Bigham sold 12,250 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $4.68, for a total transaction of $57,330.00. Following the completion of the transaction, the chairman now directly owns 542,167 shares in the company, valued at approximately $2,537,341.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Evan Loh sold 9,595 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $4.75, for a total transaction of $45,576.25. Following the transaction, the chief executive officer now owns 552,008 shares of the company’s stock, valued at $2,622,038. The disclosure for this sale can be found here. Insiders have sold a total of 32,709 shares of company stock valued at $154,510 over the last 90 days. Company insiders own 8.30% of the company’s stock.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.
Further Reading: What are economic reports?
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.